Last reviewed · How we verify
NCT05239689
Clinical Study of CD38 CAR-T Cells in the Treatment of Hematological Malignancies
Status unknown
EARLY_PHASE1
Last updated 15 February 2022
What this trial tests
EARLY_PHASE1 trial testing CD38 CAR T-cells in AML in 36 participants. Status unknown.
Timeline
28 February 2022
Primary endpoint
5 December 2024
5 December 2024
5 December 2024
Quick facts
| Lead sponsor | Zhejiang University |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 36 |
| Start date | 28 February 2022 |
| Primary completion | 5 December 2024 |
| Estimated completion | 5 December 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- CD38 CAR T-cells — full drug profile →
Conditions studied
- AML — all drugs for AML →
Sponsor
Zhejiang University
Who can join
Eligibility, any sex, with AML. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Clinical Study on the Safety and Effectiveness of CD38 CAR-T Cells in the Treatment of CD38-positive Hematological Malignancies
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Characteristics of the cancer stem cell niche and therapeutic strategies.
Ju F, Atyah MM, Horstmann N, Gul S, et al · · 2022 · cited 84× · PMID 35659296 · DOI 10.1186/s13287-022-02904-1 -
CAR-T cell therapy for cancer: current challenges and future directions.
Zugasti I, Espinosa-Aroca L, Fidyt K, Mulens-Arias V, et al · · 2025 · cited 81× · PMID 40610404 · DOI 10.1038/s41392-025-02269-w -
Recent Advances in Immune-Based Therapies for Acute Myeloid Leukemia.
Restelli C, Ruella M, Paruzzo L, Tarella C, et al · · 2024 · cited 36× · PMID 38904305 · DOI 10.1158/2643-3230.bcd-23-0202 -
Biomarkers as targets for CAR-T/NK cell therapy in AML.
Shao R, Li Z, Xin H, Jiang S, et al · · 2023 · cited 32× · PMID 37330575 · DOI 10.1186/s40364-023-00501-9 -
Infusion and delivery strategies to maximize the efficacy of CAR-T cell immunotherapy for cancers.
Gu X, Zhang Y, Zhou W, Wang F, et al · · 2024 · cited 21× · PMID 39061100 · DOI 10.1186/s40164-024-00542-2 -
Targets for chimeric antigen receptor T-cell therapy of acute myeloid leukemia.
Schorr C, Perna F. · · 2022 · cited 21× · PMID 36605213 · DOI 10.3389/fimmu.2022.1085978 -
Proteomic Characterization of Acute Myeloid Leukemia for Precision Medicine.
Casado P, Cutillas PR. · · 2023 · cited 15× · PMID 36805445 · DOI 10.1016/j.mcpro.2023.100517 -
A perspective of immunotherapy for acute myeloid leukemia: Current advances and challenges.
Chen Y, Wang J, Zhang F, Liu P. · · 2023 · cited 13× · PMID 37153761 · DOI 10.3389/fphar.2023.1151032
Verify or expand the search:
- PubMed search for NCT05239689
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for AML
Currently open trials in the same condition.
- NCT06611839 — Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AML · Phase 1, PHASE2 · recruiting
- NCT07163728 — Leptin: A Marker for AML Chemo-Sensitivity · recruiting
- NCT06973668 — A Randomized Study to Compare Post-transplant Cyclophosphamide, Sirolimus, Ruxolitinib and Post-transplant Cyclophospham · Phase 2 · recruiting
- NCT07126782 — The Efficacy and Safety Assessment of Allogeneic γδ T Cells in Patients With MRD-positive AML After Allo-HSCT · EARLY_PHASE1 · recruiting
- NCT06717958 — Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients With Acute M · Phase 2 · recruiting
Other Zhejiang University trials
Trials by the same sponsor.
- NCT07487402 — Safety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurr · EARLY_PHASE1 · not yet recruiting
- NCT07480044 — A Phase II Clinical Two-Stage Study of Transcranial Magnetic Stimulation in Preventing Postoperative Delirium in Elderly · NA · not yet recruiting
- NCT07467005 — Video Double-Lumen Tube for Secondary Pulmonary Resection · NA · not yet recruiting
- NCT07429461 — Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia · EARLY_PHASE1 · recruiting
- NCT07240766 — HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT05239689 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Zhejiang University
- Last refreshed: 15 February 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05239689.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing